Table 1.
Characteristics of study population and azathioprine intake details at enrollment
| Characteristics | Case (n=15) | Control (n=14) | P |
|---|---|---|---|
| Age (years) mean±SD | 32.47±11.22 | 26.64±7.49 | 0.11 |
| Gender (%) | |||
| Male | 13.33 | 7.14 | 0.99 |
| Female | 86.67 | 92.86 | |
| Indication for AZA (n) | |||
| SLE | 10 | 11 | 0.57 |
| MCTD | 3 | 3 | |
| ANCA vasculitis | 1 | ||
| Scleroderma | 1 | ||
| AZA dose (mg) | |||
| Minimum | 50 | 50 | NS |
| Maximum | 100 | 100 | |
| Leukocyte count (cells/mm) | |||
| Minimum | 1200 | 4100 | <0.0001 |
| Maximum | 2800 | 8900 |
SLE=Systemic lupus erythematosus, MCTD=Mixed connective tissue disorder, ANCA=Antineutrophil cytoplasmic antibody, NS=Not significant, SD=Standard deviation, AZA=Azathioprine